August 3, 2026
When CENTOGENE APAC officially opened an office in Taiwan, the team wanted the moment to mean something beyond the occasion itself. To mark the milestone, and in the spirit of CENTOGENE’s 20th anniversary as a global rare disease company, the APAC office donated Whole Exome Sequencing (WES) solutions to the Taiwan Foundation for Rare Disorders (TFRD). It was a deliberate and heartfelt gesture: a way of saying that our presence here is also about becoming part of this community.
Two decades in the rare disease sector have taught us something that no data point can fully capture. Behind every sample, every sequencing result, every report that reaches a clinician’s desk, there is a family somewhere waiting for a light at the end of a very long tunnel. This anniversary felt like the right moment to give back to the communities we have always existed to serve.
For Andy Chang, CEO APAC, this milestone carries a meaning that goes beyond strategy.
“Having worked across this region for years, I’ve seen firsthand the challenges families face in getting a timely diagnosis. Bringing CENTOGENE to APAC, and to Taiwan specifically, was about opening access to more advanced solutions for patients and giving back to the community I come from, making sure families here have the same chance in getting answers as anyone else around the world. “
– Andy Chang, CEO APAC, CENTOGENE APAC
Finding Roots in the Community: A Visit to Rare Disease Welfare Center
In April, CENTOGENE APAC General Manager Emily Liang, attended the 4th Osmanthus Music Festival and Rare Disease Family Day at Rare Disease Welfare Center, a healing sanctuary nestled in Guanxi, Hsinchu – built by TFRD in 2022 to offer rare disease families a place to reconnect and find strength together.
Walking through the place, listening to the music, and sitting with families that day, Emily found herself moved in ways that no conference room or clinical report could replicate.
“What stayed with me wasn’t just the resilience of the patients. It was the families — the mothers, the fathers, the siblings. The ones who show up calm and steady through storms, day after day, without recognition, without rest.”
– Emily Liang, North East Asia General Manager, CENTOGENE APAC
Rare disease is rarely a weight carried by one person alone. It spreads quietly through an entire family: into the sleepless nights, the appointments with doctors who do not yet have answers, and the slow, demanding work of learning to hold onto hope without any certainty to hold onto.
The afternoon in Guanxi reshaped how we think about our role – not simply as a company providing testing solutions, but a companion in the journey, the one that fights alongside them.
A New Collaboration: CentoGenome MOx 1.0 for Taiwanese Patients
Our commitment to Taiwan’s rare disease community continues with a new collaboration program between CENTOGENE and TFRD. Running from June 1 to November 30, 2026, this initiative makes the CentoGenome MOx 1.0 test accessible to Taiwanese patients who have previously undergone WES but remained without confirmed diagnosis.
“For too many families, finding an answer has meant years of uncertainty. Having CENTOGENE’s advanced solutions now available in Taiwan, patients who were once left without answers can move beyond the limits of conventional methods and gain deeper insights into their condition. This means new hope, and ultimately better outcomes and quality of life for patients.”
– Ruth Chen, CEO, Taiwan Foundation for Rare Disorders (TFRD)
For further details, visit the program page.
